Abstract
This open-label study examined the potential efficacy of paroxetine in the treatment of children and adolescents diagnosed with dysthymia over a period of 3 months. Seven subjects were evaluated by the Hamilton Depression Rating Scale (HAM-D), by the Clinical Global Impression Severity of Illness Scale (CGI-S), and the Clinical Global Impression Improvement Scale (CGI-I). Seventy-one percent of patients had a satisfactory response, suggesting the efficacy of paroxetine in children with dysthymia.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Antidepressive Agents, Second-Generation / adverse effects
-
Antidepressive Agents, Second-Generation / therapeutic use*
-
Child
-
Dysthymic Disorder / drug therapy*
-
Dysthymic Disorder / psychology
-
Female
-
Humans
-
Male
-
Nausea / chemically induced
-
Pain / chemically induced
-
Paroxetine / adverse effects
-
Paroxetine / therapeutic use*
-
Psychiatric Status Rating Scales
Substances
-
Antidepressive Agents, Second-Generation
-
Paroxetine